4.6 Review

Effects of Fibrin Clot Inhibitors and Statins on the Intravesical Bacille Calmette-Guerin Therapy for Bladder Cancer: A Systematic Review and Meta-Analysis

期刊

FRONTIERS IN ONCOLOGY
卷 11, 期 -, 页码 -

出版社

FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2021.614041

关键词

statins; fibrin clot inhibitors; Bacille Calmette-Guerin; bladder cancer; prognosis

类别

资金

  1. National Natural Science Foundation of China [81873626, 81902592]
  2. Hunan Province Key RD Program [2019SK2202]
  3. Xiangya Hospital Youth Fund [2018Q09]

向作者/读者索取更多资源

This study indicates that fibrin clot inhibitors and statins have no significant impact on the oncological prognosis of BCG therapy for bladder cancer, and there is no need to stop using them or switch to other drugs during treatment. Large-scale multi-center prospective research is still required to confirm these findings.
Objective To assess the effect of fibrin clot inhibitors (aspirin, clopidogrel, and warfarin) and statins on intravesical BCG therapy. Method A systematic literature search was carried out through PubMed, Embase, and the Cochrane Central Search Library in March 2020. Accumulative analyses of odds ratios (ORs), hazard ratio (HR), and corresponding 95% confidence intervals (CIs) were performed. All analyses were performed by using Review Manager software version 5.3 and Stata 15.1. Results Four cohort studies and nine case-control studies containing 3,451 patients were included. The pooled analysis indicated that statins (HR = 1.00; 95%CI, 0.82 to 1.22; p = 1.00) and fibrin clot inhibitors (HR = 1.01; 95%CI, 0.64 to 1.59; p = 0.98) did not affect the efficacy of BCG on recurrence-free survival. The cumulative analysis showed that statins (HR = 0.79; 95%CI, 0.41 to 1.49; p = 0.46) and fibrin clot inhibitors (HR = 1.62; 95%CI, 0.90 to 2.91; p = 0.11) did not affect the efficacy of BCG on progression-free survival. There were no differences on cancer-specific survival (HR = 1.68; 95%CI, 0.64 to 4.40; p = 0.29) and overall survival (HR = 1.13; 95%CI, 0.73 to 1.78; p = 0.58) after taking statins. Conclusion The present study shows that the application of fibrin clot inhibitors and statins do not influence the efficacy of BCG on oncological prognosis. Consequently, we do not need to stop using them or change to other drugs during intravesical BCG treatment. However, large-scale multi-center prospective research is still needed to confirm the above conclusions.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据